Skip to main content

Table 2 Demographics of PNH patients at baseline compared to general population

From: Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

Variable Began trial on eculizumab (n = 219) Began trial on ravulizumab (n = 222) General population (n = 15,386)
Mean SD Mean SD Mean SD
Age 47.38 15.30 45.67 14.83 53.57 15.375
Years Since Diagnosis 8.93 8.84 9.33 8.70 NA  
Baseline BMI (kg/m2) 25.25 4.23 24.83 4.71   
  # % # % # %
Region       
 Europe 113 51.60 106 47.75 13,373 86.92
 Japan 22 10.05 25 11.26 0 0.00
 Latin America 13 5.94 9 4.05 0 0.00
 North America 16 7.31 17 7.66 2013 13.08
 Rest of Asia  Pacific 55 25.11 65 29.28 0 0.00
Female 102 46.58 107 48.20 7650 49.72